Literature DB >> 3858668

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity.

G B Appel, C B Blum, S Chien, C L Kunis, A S Appel.   

Abstract

Although hyperlipidemia is a common feature of the nephrotic syndrome, the distribution of cholesterol among the plasma lipoproteins and the mechanism of the enhanced hepatic synthesis of lipoprotein lipids are not well understood. We studied the distribution of cholesterol among the plasma lipoproteins, as well as the relation between total cholesterol and plasma albumin concentration, oncotic pressure, and viscosity in 20 consecutive adult patients with uncomplicated nephrotic syndrome. The total plasma cholesterol (mean +/- S.D., 302 +/- 100 mg per deciliter [7.8 +/- 2.6 mmol per liter]) and low-density-lipoprotein cholesterol concentrations (215 +/- 89 mg per deciliter [5.6 +/- 2.3 mmol per liter]) were elevated in most patients, but the high-density-lipoprotein cholesterol level was normal or low (46 +/- 18 mg per deciliter [1.2 +/- 0.5 mmol per liter]) in 95 per cent of the patients. Thus, many hypercholesterolemic patients with unremitting nephrotic syndrome may be at increased risk for atherosclerotic heart disease. A significant inverse correlation was found between the total plasma cholesterol concentration and both the plasma albumin concentration (r = -0.528) and the plasma oncotic pressure (r = -0.674), but not the plasma viscosity (r = +0.319). Enhanced hepatic synthesis of lipoprotein lipids may be stimulated by a decreased plasma albumin concentration or oncotic pressure but does not appear to be due to changes in plasma viscosity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3858668     DOI: 10.1056/NEJM198506133122404

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

Review 1.  Chronic kidney disease and its complications.

Authors:  Robert Thomas; Abbas Kanso; John R Sedor
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

Review 2.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

Review 3.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

4.  Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients.

Authors:  M D Feher; J M Falko
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

5.  Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.

Authors:  Pankaj Hari; Priyanka Khandelwal; Amit Satpathy; Smriti Hari; Ranjeet Thergaonkar; R Lakshmy; Aditi Sinha; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-08-08       Impact factor: 3.714

6.  Serum lipoprotein (a) concentration in patients with nephrotic syndrome and its clinical implication.

Authors:  X Yang; H Wang; Z Zhu; A Deng
Journal:  J Tongji Med Univ       Date:  1998

7.  Homeostatic regulation of hepatocyte nuclear transcription factor 1 expression in cultured hepatoma cells.

Authors:  A Pietrangelo; D A Shafritz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

Review 8.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

9.  Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Santamaria; J D Best
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

10.  Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a).

Authors:  H Dieplinger; C Lackner; F Kronenberg; C Sandholzer; K Lhotta; F Hoppichler; H Graf; P König
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.